Chappell L L, Dadachova E, Milenic D E, Garmestani K, Wu C, Brechbiel M W
Radioimmune and Inorganic Chemistry Section, ROB, DCS, Bethesda, Maryland 20892-1002, USA.
Nucl Med Biol. 2000 Jan;27(1):93-100. doi: 10.1016/s0969-8051(99)00086-4.
Radioisotopes of Pb(II) have been of some interest in radioimmunotherapy and radioimmunoimaging (RII). However, the absence of a kinetically stable bifunctional chelating agent for Pb(II) has hampered its use for these applications. 203Pb (T(1/2) = 52.02 h) has application potential in RII, with a gamma-emission that is ideal for single photon emission computerized tomography, whereas 212Pb (T(1/2) = 10 h) is a source of highly cytotoxic alpha-particles via its decay to its 212Bi (T(1/2) = 60 min) daughter. The synthesis of the novel bifunctional chelating agent 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra- (2-carbamoyl methyl)-cyclododecane (4-NCS-Bz-TCMC) is reported herein. The Pb[TCMC]2+ complex was less labile to metal ion release than Pb[DOTA]2- at pH 3.5 and below in isotopic exchange experiments. In addition to increased stability to Pb2+ ion release at low pH, the bifunctional TCMC ligand was found to have many other advantages over the bifunctional 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid (DOTA) ligand. These include a shorter and more straightforward synthetic route, a more efficient conjugation reaction to a monoclonal antibody (mAb), with a higher chelate to protein ratio, a higher percent immuroreactivity, and a more efficient radiolabeling reaction of the mAb-ligand conjugate with 203Pb.
铅(II)的放射性同位素在放射免疫治疗和放射免疫显像(RII)中受到了一定关注。然而,缺乏一种动力学稳定的用于铅(II)的双功能螯合剂阻碍了其在这些应用中的使用。203Pb(半衰期T(1/2)=52.02小时)在RII中具有应用潜力,其γ发射非常适合单光子发射计算机断层扫描,而212Pb(半衰期T(1/2)=10小时)通过衰变产生其212Bi(半衰期T(1/2)=60分钟)子体,是一种高细胞毒性α粒子的来源。本文报道了新型双功能螯合剂2-(4-异硫氰酸苄基)-1,4,7,10-四氮杂-1,4,7,10-四(2-氨甲酰甲基)-环十二烷(4-NCS-Bz-TCMC)的合成。在同位素交换实验中,在pH 3.5及以下时,Pb[TCMC]2+络合物比Pb[DOTA]2-对金属离子释放的稳定性更低。除了在低pH下对Pb2+离子释放具有更高的稳定性外,还发现双功能TCMC配体比双功能1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)配体具有许多其他优点。这些优点包括合成路线更短、更直接,与单克隆抗体(mAb)的偶联反应更高效,螯合物与蛋白质的比例更高,免疫反应性百分比更高,以及mAb-配体缀合物与203Pb的放射性标记反应更高效。